MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA

• US 20110190221A1
• Filed: 03/30/2009
• Published: 08/04/2011
• Est. Priority Date: 03/28/2008
• Status: Abandoned Application

• Current Assignee: Apellis Pharmaceuticals, Inc.
• Original Assignee: Apellis AG
• Inventors: Olson, Paul, Francois, Cedric, Deschatelets, Pascal
• Application Number:
  US12/935,251
• Publication Number:
  US 20110190221A1
• Time in Patent Office: Days
• US Class Current: 514/20.9
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/162 from virus
• CPC Class Codes: A61K 38/1725 Complement proteins, e.g. anaphylatoxin, C3a or C5a
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury.

Claims

1. A method of treating an individual who has suffered a traumatic injury comprising administering a complement activation inhibitor to the individual within 24 hours after the injury, wherein the complement inhibitor (i) acts at or above the level of C3 activation;

and (ii) does not cause significant depletion or irreversible inactivation of an unactivated complement component.

2. The method of claim 1, wherein the complement activation inhibitor inhibits depletion of C3.

3. The method of claim 1, wherein the complement activation inhibitor acts on a complement component selected from the group consisting of:

C1, C2, C3, C4, factor B, factor D, or an active fragment of one or more of the foregoing.

5. The method of claim 1, wherein the complement inhibitor has an average half-life of 24 hours or less in humans under normal conditions.

20. The method of claim 1, wherein the complement inhibitor inhibits a C3 convertase.

21. The method of claim 1, wherein the complement inhibitor binds to C3 and inhibits its activation.

22. The method of claim 1, wherein the complement inhibitor comprises a compstatin analog.

23. The method of claim 1, wherein the complement activation inhibitor comprises a compstatin analog having a sequence selected from the group consisting of:

SEQ ID NOs;

14, 21, 28, 29, 30, 32, 33, 34, or 36.

24. The method of claim 1, wherein the complement activation inhibitor comprises a VCCP or VCIP or complement inhibiting altered version thereof.

25. The method of claim 1, wherein the complement activation inhibitor comprises a mammalian complement regulatory protein or a complement inhibiting altered version thereof.

26. The method of claim 1, wherein the complement activation inhibitor comprises a mammalian complement control protein or a complement inhibiting fragment or altered version thereof, wherein the mammalian complement control protein is complement factor H(CFH), decay accelerating factor (DAF), or membrane cofactor protein (MCP).

38. The method of claim 1, further comprising administering to the individual an unactivated complement component.

41. The method of claim 38, wherein the complement component is administered at least 24 hours after the injury.

44. The method of claim 38, wherein the complement component is an at least partially purified or recombinantly produced protein.

53. The method of claim 1, comprising administering a complement activation inhibitor to the individual in the immediate post-trauma period in an amount effective to reduce trauma-induced complement depletion by at least 50%, wherein the complement inhibitor does not itself cause significant depletion or irreversible inactivation of an unactivated complement component, and wherein the complement inhibitor is administered in an amount such that at least 90% of the complement inhibitor administered is gone from the blood within 1 week after the injury.

4. (canceled)

6-19. -19. (canceled)

27-37. -37. (canceled)

39-40. -40. (canceled)

42-43. -43. (canceled)

45-52. -52. (canceled)

54-135. -135. (canceled)